Lite Strategy (LITS) Interest Expenses (2011 - 2026)
Lite Strategy (LITS) posted quarterly Interest Expenses of $838000.0 for Q1 2026, up 52.92% year-over-year from $548000.0 in Q1 2025, and down 1.53% quarter-over-quarter from $851000.0 in Q4 2025.
Lite Strategy (LITS) Interest Expenses (2011 - 2026) Analysis & Trends
Lite Strategy's Interest Expenses history runs 15 years deep, the most recent figure standing at $838000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 52.92% year-over-year to $838000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 82.97% YoY), while the FY2025 annual figure was $73.7 million, up 441.43% from the prior year.
- Interest Expenses for Q1 2026 stood at $838000.0, down from $851000.0 in the prior quarter.
- The five-year high for Interest Expenses was $73.7 million in Q2 2025, with the low at $3000.0 in Q3 2025.
- The 5-year median for Interest Expenses is $584000.0 (2024), against an average of $7.9 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses sank 99.29% in 2022, then surged 4358.68% in 2023.
- Lite Strategy's Interest Expenses stood at $4.1 million in 2022, then slumped by 85.92% to $583000.0 in 2023, then slumped by 33.28% to $389000.0 in 2024, then soared by 118.77% to $851000.0 in 2025, then fell by 1.53% to $838000.0 in 2026.
- Business Quant data shows LITS's Interest Expenses at $838000.0 in Q1 2026, $851000.0 in Q4 2025, and $3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 838,000.00 |
| Mar 31, 2026 | 838,000.00 |
| Dec 31, 2025 | 851,000.00 |
| Dec 31, 2025 | 851,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 73.70 Mn |
| Jun 30, 2025 | 73.70 Mn |
| Mar 31, 2025 | 548,000.00 |
| Mar 31, 2025 | 548,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Dec 31, 2024 | 389,000.00 |
| Sep 30, 2024 | 357,000.00 |
| Sep 30, 2024 | 357,000.00 |
| Jun 30, 2024 | 11.86 Mn |
| Jun 30, 2024 | 11.86 Mn |
| Mar 31, 2024 | 584,000.00 |
| Mar 31, 2024 | 584,000.00 |
| Dec 31, 2023 | 583,000.00 |
| Dec 31, 2023 | 583,000.00 |